Product Description
Mechanisms of Action: FXa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Angina, Stable|Non-ST Elevated Myocardial Infarction|Angina, Unstable|Acute Coronary Syndrome
Phase 2: Coronary Thrombosis|Venous Thrombosis|Acute Coronary Syndrome|Coronary Artery Disease|Coronary Disease
Phase 1: Kidney Diseases|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| POP6537 | P1 |
Completed |
Kidney Diseases |
2011-07-01 |
2019-03-19 |
Treatments |
|
| POP6207 | P1 |
Completed |
Other |
2011-04-01 |
2019-03-19 |
Treatments |
|
| SEPIA-ACS 1/TIMI 42 | P2 |
Completed |
Acute Coronary Syndrome |
2009-03-01 |
2025-07-02 |
Treatments |
|
| SEPIA-ACS1 | P2 |
Completed |
Coronary Artery Disease|Acute Coronary Syndrome |
2008-10-01 |
2019-03-21 |
Treatments |
|
| The SEPIA-PCI Trial | P2 |
Completed |
Coronary Disease |
2005-09-01 |
2022-03-12 |
Treatments |
|
| SEPIA-PCI | P2 |
Completed |
Coronary Thrombosis|Venous Thrombosis |
None |
2019-03-21 |
Treatments |
|
| TAO | P3 |
Completed |
Acute Coronary Syndrome |
2013-05-06 |
2022-03-13 |
||
| TAO | P3 |
Completed |
Angina, Stable|Angina, Unstable|Acute Coronary Syndrome|Non-ST Elevated Myocardial Infarction |
2013-05-01 |
2019-03-19 |
Treatments |